Dramatic volume reduction of a large GH/TSH secreting pituitary tumor with short term octreotide therapy

Pituitary

Volumn 8, Issue 2, 2005, Pages 89-91

  Atkinson, John L D ^a   Abboud, Charles F ^a   Lane, John I ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acromegaly; Octreotide; Pituitary tumor; Tumor shrinkage

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN; THYROTROPIN;

ACROMEGALY; ADULT; ARTICLE; CANCER SURGERY; CARPAL TUNNEL SYNDROME; CASE REPORT; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CRANIOTOMY; FEMALE; GAMMA KNIFE RADIOSURGERY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS TUMOR; INVAGINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; SPLINT; TEMPORAL LOBE; THYROTROPIN RELEASE; TUMOR VOLUME;

FEMALE; HUMAN GROWTH HORMONE; HUMANS; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; THYROTROPIN;

EID: 33644505863     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-005-3279-2     Document Type: Article

References (13)

1. Barkan A, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988;67:1040-1048.
2. Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegaly patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000;85:4099-4103.
3. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-1, and tumour size. J Clin Endocrinol Metab 2002;87(10):4554-4563.
4. Colao A, Ferone D, Cappabianca P, et al. Effects of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308-3314.
5. Colao A, Ferone F, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-2786.
6. Cozzi R, Barausse M, Sberna M, et al. Lanreotide 60 mg, a longer-acting somatostatin analog: Tumor shrinkage and hormonal normalization in acromegaly. Pituitary 2000;3:231-238.
7. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-699.
8. James RA, Chatterjee S, White MC, Hall K, Moller N, Kendall-Tyler P. Continuous infusion of octreotide in acromegaly. Lancet 1989;2(8761):1083-1087.
9. Lundin P, Engstrom BE, Karlsson FA, et al. Longterm octreotide therapy in growth hormone-secreting pituitary adenomas: Evaluation with serial MR. Am J Neuroradiol 1997;18:765-772.
10. Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034-3040.
11. Sassolas G, Harris AG, James-Didier A, the French SMS 201-995 acromegaly study group. Longterm effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990;71:391-397.
12. Vance ML, Harris AG. Longterm treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 1991;151:1573-1578.
13. Lindsay JR, Harding JA, Ellis PK, Sheridan B, Atkinson AB. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with Octreotide in the absence of marked tumour shrinkage. Pituitary 2003;6:209-214.